{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-022162","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2024-07-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.853367+00:00","generated_at":"2026-05-31T23:29:21.523260+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pulse Biosciences closes $60M rights offering at $10/unit, oversubscribed 138%","bullets":["Raised $60M gross from 6M units; each unit = 1 share + 2 warrants to buy 0.5 share at $11.","Subscriptions exceeded $83M from 800+ accounts, including Executive Chairman Robert Duggan.","Post-offering shares outstanding: 61,228,332; warrants for up to ~6M additional shares issued.","Proceeds to fund CellFX nsPFA products: Percutaneous Electrode, Cardiac Clamp, 360° Catheter.","Warrants exercisable immediately for 5 years; redeemable if stock exceeds $16.50 or $22 for 20 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-022162","json":"https://secwatch.observer/filing/0001437749-24-022162.json","markdown":"https://secwatch.observer/filing/0001437749-24-022162.md","text":"https://secwatch.observer/filing/0001437749-24-022162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924022162/0001437749-24-022162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924022162/plse20240702_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:29:21.523260+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}